Triglycerides: What They Tell Us About Metabolic and Cardiovascular Health

Triglycerides are easy to overlook on a lipid panel. LDL cholesterol usually receives most of the attention, while triglycerides are sometimes treated as a dietary footnote: eat fewer sweets, lose some weight, repeat the test later.

That misses useful information, but the opposite mistake is possible too. An elevated triglyceride concentration is not a stand-alone diagnosis of insulin resistance, and a low triglyceride level does not guarantee that someone's metabolic or cardiovascular risk is low.

Triglycerides become much more informative when they are interpreted with the rest of the lipid profile, apoB or non-HDL cholesterol when appropriate, glucose metabolism, body composition, alcohol intake, medications, thyroid and kidney function, and the patient's overall cardiovascular risk.

In preventive cardiology, the question is not simply whether triglycerides are high. We want to know why they are high, what lipoprotein pattern accompanies them, and whether the finding changes what we should do.

What Are Triglycerides?

A triglyceride consists of three fatty acids attached to glycerol. Triglycerides are an efficient way for the body to transport and store energy.

After a meal, dietary triglycerides are carried primarily in chylomicrons. Between meals, the liver packages triglycerides into very-low-density lipoprotein, or VLDL. As these particles circulate, triglycerides are progressively removed and used or stored by tissues.

This normal physiology is why triglycerides vary more from meal to meal than LDL cholesterol. A nonfasting triglyceride measurement is therefore not inherently a bad test. For routine cardiovascular assessment, nonfasting lipid panels are often acceptable. A fasting measurement becomes more useful when triglycerides are markedly elevated, when metabolic syndrome is being assessed, when a genetic lipid disorder is suspected, or when the clinician needs to determine pancreatitis risk more precisely.

When Is a Triglyceride Level Considered High?

Common clinical definitions classify fasting triglycerides below 150 mg/dL as normal. Mild to moderate elevation generally begins at 150 mg/dL fasting or approximately 175 mg/dL nonfasting and extends to below 500 mg/dL.

Triglycerides of 500 mg/dL or greater are considered severe. Levels around 1,000 mg/dL and above deserve particular attention because chylomicrons may accumulate and the risk of acute pancreatitis increases substantially.

A single mildly elevated result should still be interpreted in context. A recent meal, alcohol intake, acute illness, poorly controlled diabetes, medication changes and laboratory variability can all influence the measurement.

Why Triglycerides Rise in Insulin Resistance

Insulin resistance frequently produces a recognizable lipid pattern. Fatty acids are delivered to the liver in greater amounts, hepatic triglyceride production increases, and the liver secretes more triglyceride-rich VLDL particles. Clearance of those particles can also become impaired.

The result may be elevated triglycerides, lower HDL cholesterol and a shift toward cholesterol-depleted LDL particles. This is sometimes referred to as atherogenic dyslipidemia and is common in people with insulin resistance, metabolic syndrome and type 2 diabetes.

Triglycerides can therefore provide a clue that metabolic dysfunction is present, but they should not be used as a substitute for evaluating glucose metabolism.

When the history or metabolic picture warrants it, triglycerides can be interpreted alongside fasting insulin, glucose, hemoglobin A1c and, in selected circumstances, HOMA-IR.

Waist circumference and direct assessment of body composition can provide additional information because visceral adiposity is strongly associated with insulin resistance and hypertriglyceridemia.

High Triglycerides Do Not Always Mean Someone Eats Too Much Sugar

Diet can contribute substantially, particularly diets that produce chronic energy surplus or contain large amounts of refined carbohydrate, added sugars or alcohol. But assigning elevated triglycerides to diet without looking further can miss the reason they are elevated.

Common secondary contributors include poorly controlled diabetes, excess visceral adiposity, substantial alcohol consumption, hypothyroidism, chronic kidney disease and certain medications. Estrogens taken orally, glucocorticoids, some antipsychotic medications, retinoids, certain HIV therapies and other drugs can raise triglycerides in susceptible patients.

Genetics also matters. Some people inherit a tendency toward elevated triglyceride-rich lipoproteins, and rare genetic disorders can produce extreme elevations.

When triglycerides are unexpectedly high or rise abruptly, the clinical evaluation should look for the explanation rather than simply advising the patient to “eat better.”

Triglycerides and Cardiovascular Disease

The relationship between triglycerides and atherosclerosis is more nuanced than saying that triglyceride molecules themselves simply accumulate in the arterial wall.

Triglyceride-rich lipoproteins and their remnant particles also carry cholesterol. As triglycerides are removed from VLDL and chylomicron particles, cholesterol-enriched remnants remain in circulation. These remnant particles can enter the arterial wall and contribute to atherosclerosis.

This understanding is reflected in the 2026 ACC/AHA dyslipidemia guideline, which specifically recognizes triglyceride-rich remnant particles as part of atherogenic lipoprotein risk.

That is why an elevated triglyceride level should not lead us away from LDL-C or apoB. It often makes those measurements more informative.

Why ApoB Is Especially Useful When Triglycerides Are Elevated

Each atherogenic particle carries one molecule of apoB. Measuring apoB therefore gives us an estimate of the number of circulating atherogenic lipoprotein particles rather than simply measuring how much cholesterol happens to be carried inside them.

When triglycerides are elevated, the amount of cholesterol carried in an individual LDL particle can vary substantially. Two people can have similar LDL-C concentrations but quite different numbers of atherogenic particles.

The 2026 ACC/AHA guideline specifically notes that apoB can improve risk assessment when triglycerides are above approximately 200 mg/dL, in diabetes, and in other situations where LDL-C may underestimate residual lipoprotein-related risk.

Triglycerides tell us something about the metabolic and lipoprotein environment. ApoB tells us how many atherogenic particles are circulating within it.

Non-HDL Cholesterol Is Useful Too

Non-HDL cholesterol is calculated by subtracting HDL cholesterol from total cholesterol. The result captures the cholesterol contained in LDL, VLDL remnants, intermediate-density lipoproteins and other apoB-containing particles.

Unlike calculated LDL-C, non-HDL cholesterol remains useful when triglycerides are elevated because it includes cholesterol carried in triglyceride-rich remnant particles.

The 2026 dyslipidemia guideline again uses both LDL-C and non-HDL-C treatment goals, particularly in patients at increased cardiovascular risk.

Triglycerides Are Not a Replacement for Lipoprotein(a)

Lipoprotein(a), or Lp(a), is primarily genetically determined and represents a different cardiovascular risk pathway. A person can have low triglycerides and very high Lp(a), high triglycerides and low Lp(a), or both.

This is why a lipid evaluation built around a single “good” number is incomplete. The 2026 guideline recommends measuring Lp(a) at least once in adulthood because routine lifestyle changes have relatively little effect on it and an elevated concentration may meaningfully alter lifetime cardiovascular risk.

What About the Triglyceride-to-HDL Ratio?

The triglyceride-to-HDL cholesterol ratio is sometimes used as a rough clue to insulin-resistant dyslipidemia. A high ratio often accompanies elevated triglycerides, low HDL cholesterol and metabolic syndrome.

It can be descriptive, but it is not a substitute for measuring apoB, assessing glucose metabolism or evaluating the patient directly. There is no universal triglyceride-to-HDL treatment target endorsed by major cardiovascular guidelines.

It is better used as another piece of pattern recognition than as a stand-alone diagnostic test.

Severe Hypertriglyceridemia Is a Different Clinical Situation

Once triglycerides reach 500 mg/dL, and especially when they approach or exceed 1,000 mg/dL, the clinical priority changes. Cardiovascular prevention remains important, but preventing acute pancreatitis becomes increasingly urgent.

These patients require a review for secondary causes such as uncontrolled diabetes, alcohol use, medications, kidney disease and hypothyroidism. Very high levels may also indicate an inherited disorder of triglyceride metabolism.

When triglycerides are around 1,000 mg/dL or higher, treatment may require a very-low-fat diet temporarily, elimination of alcohol, aggressive control of hyperglycemia when present and prescription triglyceride-lowering medication.

This is not the same dietary conversation we have with someone whose triglycerides are 180 mg/dL. Severe hypertriglyceridemia deserves individualized medical management.

Familial Chylomicronemia Is Rare, but It Should Not Be Missed

Familial chylomicronemia syndrome is a rare genetic disorder in which triglycerides can remain extremely elevated because the body cannot normally clear chylomicrons.

Patients may experience recurrent pancreatitis, abdominal pain, eruptive xanthomas or lipemia retinalis. The treatment strategy differs considerably from ordinary insulin-resistant hypertriglyceridemia.

Newer therapies directed at apolipoprotein C-III are now available for selected patients with familial chylomicronemia syndrome. This is specialist territory and should not be confused with the much more common mild or moderate triglyceride elevations seen with metabolic disease.

What Actually Lowers Triglycerides?

For mild to moderate hypertriglyceridemia, treatment begins with the reason the triglycerides are elevated.

When excess adiposity is contributing, meaningful weight loss can lower triglycerides substantially. Regular aerobic activity improves triglyceride clearance. Reducing added sugars, refined starches and excessive energy intake can help, particularly in insulin-resistant patients. Alcohol deserves specific attention because it can raise triglycerides dramatically in susceptible people.

A Mediterranean-style eating pattern with adequate protein, fiber-rich plants, minimally processed carbohydrates and unsaturated fats is generally more useful for long-term cardiometabolic health than chasing a single triglyceride-lowering food.

The dietary approach changes when triglycerides are severely elevated. Patients at risk for chylomicronemia and pancreatitis may temporarily need a much more restrictive low-fat or very-low-fat diet under clinical supervision.

Where Statins Fit

A common misconception is that triglyceride elevation should automatically lead to a triglyceride-specific drug.

For most people whose main concern is atherosclerotic cardiovascular disease, statins remain the pharmacologic foundation when lipid-lowering therapy is indicated. Statins primarily reduce apoB-containing particles and LDL cholesterol, but they also produce a modest reduction in triglycerides.

The 2026 ACC/AHA guideline continues to place statin therapy at the center of cardiovascular risk reduction in patients with persistent hypertriglyceridemia. Additional therapy depends on the patient's cardiovascular risk, triglyceride concentration and whether pancreatitis prevention has become a priority.

Prescription Omega-3 Therapy Is Not the Same as a Fish-Oil Supplement

Prescription omega-3 fatty acids can lower triglycerides, but formulations differ and cardiovascular outcome data cannot simply be generalized from one product to another.

Icosapent ethyl, a purified EPA formulation, reduced cardiovascular events in the REDUCE-IT trial among selected statin-treated patients at elevated cardiovascular risk who had persistent hypertriglyceridemia.

That finding does not mean that over-the-counter fish oil supplements have been shown to provide the same cardiovascular benefit. Dose, formulation, purity and the population being treated are different.

Prescription omega-3 therapy is therefore a medical treatment used for particular indications, not an interchangeable category with nutritional fish-oil supplements.

Fibrates Still Have a Role

Fibrates can reduce triglycerides substantially and remain useful, particularly when triglycerides are severely elevated and pancreatitis prevention is the immediate concern.

The evidence that fibrates routinely reduce cardiovascular events when added to contemporary statin treatment is considerably less consistent. They are therefore not a universal treatment for every person with triglycerides above 150 mg/dL.

Drug choice also matters. Gemfibrozil can interact with statins and is generally avoided when the two would be used together. Kidney function and other medications need to be considered when fibrates are prescribed.

What Does an “Optimal” Triglyceride Level Mean?

I would be cautious about creating a clinic-specific triglyceride number and calling everything above it suboptimal disease.

Fasting triglycerides below 150 mg/dL are conventionally considered normal. Cardiometabolic risk generally moves in a continuum rather than beginning abruptly at that threshold, and lower triglycerides often accompany favorable metabolic health.

But a triglyceride value of 80 mg/dL does not erase a high apoB, high Lp(a), smoking, hypertension or diabetes. Likewise, a triglyceride measurement of 170 mg/dL does not carry the same meaning in every patient.

We use the number to understand the physiology and risk, not to turn another laboratory measurement into a wellness score.

How We Interpret Triglycerides at HormoneSynergy®

We rarely look at triglycerides by themselves. Depending on the patient, the larger picture may include:

• ApoB and the overall burden of atherogenic particles
• Lipoprotein(a)
• LDL-C and non-HDL cholesterol
• Fasting insulin, glucose and hemoglobin A1c when appropriate
• HOMA-IR in selected patients
• Blood pressure
• Body composition and visceral adiposity
• Alcohol intake, nutrition, exercise and medications
• hs-CRP when inflammatory risk assessment is clinically useful

The point is not to order every biomarker simply because it exists. Testing should answer a clinical question and, ideally, change a decision.

Where Triglycerides Fit in Preventive Cardiology

Triglycerides are one piece of a much larger cardiovascular assessment. Atherosclerosis develops from prolonged exposure to atherogenic lipoproteins interacting with blood pressure, smoking, diabetes, inflammation, genetics and other risk factors over time.

The 2026 ACC/AHA dyslipidemia guideline places greater emphasis on identifying and treating atherogenic lipoprotein exposure earlier in life. It also recognizes situations in which apoB, Lp(a), non-HDL cholesterol and coronary artery calcium can improve risk assessment beyond a conventional LDL-C result.

Explore Preventive Cardiology and Silent Heart Disease Detection →

Explore Metabolic Health and Longevity Medicine →

Frequently Asked Questions

What do triglycerides measure?

Triglycerides measure the concentration of circulating triglyceride fat carried primarily in chylomicrons and VLDL-related particles. The concentration is influenced by meals, liver metabolism, insulin sensitivity, adiposity, alcohol, medications, genetics and other medical conditions.

Are high triglycerides a sign of insulin resistance?

They can be. Elevated triglycerides commonly accompany insulin resistance and metabolic syndrome, but they are not diagnostic by themselves. Diabetes, alcohol, medications, hypothyroidism, kidney disease and genetic lipid disorders can also raise triglycerides.

Can triglycerides be high when LDL cholesterol is normal?

Yes. LDL-C measures the cholesterol carried in LDL particles, while triglycerides reflect a different part of lipoprotein metabolism. When triglycerides are elevated, apoB or non-HDL cholesterol may reveal a larger burden of atherogenic particles than LDL-C alone suggests.

When do triglycerides become dangerous?

Cardiovascular risk rises across a broad range of triglyceride concentrations, but very high levels create an additional concern. Triglycerides of 500 mg/dL or greater warrant attention to pancreatitis risk, and levels around 1,000 mg/dL or above require particularly aggressive evaluation and treatment.

Should high triglycerides be treated with fish oil?

Not automatically. Prescription omega-3 formulations can lower triglycerides and icosapent ethyl has cardiovascular outcome evidence in selected high-risk statin-treated patients. Over-the-counter fish-oil supplements should not be assumed to provide the same dose, formulation or cardiovascular benefit.

Do triglycerides matter if my ApoB is low?

The result still provides information about metabolic and triglyceride-rich lipoprotein physiology, but apoB more directly reflects the total number of circulating atherogenic particles. Cardiovascular risk should be interpreted using the complete clinical picture rather than a single biomarker.

Selected Clinical References

Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation and Journal of the American College of Cardiology. 2026.

Virani SS, Morris PB, Agarwala A, et al. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia. Journal of the American College of Cardiology. 2021.

Grundy SM, Stone NJ, Bailey AL, et al. Guideline and consensus evidence informing management of hypertriglyceridemia and atherosclerotic cardiovascular risk.

Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine. 2019;380:11-22.

National Lipid Association. Clinical perspectives on dietary management of hypertriglyceridemia and dyslipidemia.

Educational use only. This article is intended for general education and does not provide a diagnosis or individualized treatment plan. Markedly elevated triglycerides, suspected familial lipid disorders and lipid-lowering medication decisions should be evaluated and managed by an appropriately licensed clinician.